La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Clearside Biomedical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Clearside Biomedical..

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

CLEARSIDE BIOMEDICAL INC

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Citigroup analyst Paul Lejuez maintains Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) with a Buy and lowers the price target from $135 to $98.

News

Price Target

Analyst Ratings

Citigroup Maintains Buy on Abercrombie & Fitch, Lowers Price Target to $98

Management

General

NMRK

Newmark Group Names Lou Alvarado As COO

Karman Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) reported quarterly earnings of $0.08 per share. This is a 166.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported $345.25 million in sales this quarter. This is a 37.71 percent increase over sales of $250.71 million the same period last year.

Earnings

KRMN

Karman Holdings FY EPS $0.08 Up From $0.03 YoY, Sales $345.25M Up From $250.71M YoY

Onestream Co-Founder Craig Colby To Transition To Chief Success Officer Effective May 1, 2025 ;Thomas Shea To Assume Role Of President

WIIM

NTHI

NeOnc Technologies shares are trading higher after the company announced near full enrollment for its Phase 1 clinical trial of NEO212 for brain cancer

- ImmuCell Corporation (Nasdaq:&nbsp;ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today&nbsp;announced preliminary, unaudited sales results for the first quarter of 2025.
Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close of the quarter. The Company expects to continue providing this prompt, preliminary report on product sales until further notice going forward.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5">Preliminary, Unaudited Total Sales Results: &nbsp;</td>
</tr>
<tr>
<td>2025</td>
<td>2024</td>
<td>$ Increase</td>
<td>% Increase</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>During the Three-Month Periods Ended March 31,</td>
<td>$8.1 million</td>
<td>$7.3 million</td>
<td>$0.8 million</td>
<td>11%</td>
</tr>
<tr>
<td>During the Six-Month Periods Ended March 31,</td>
<td>$15.8 million</td>
<td>$12.4 million</td>
<td>$3.5 million</td>
<td>28%</td>
</tr>
<tr>
<td>During the Twelve-Month Periods Ended March 31,</td>
<td>$27.3 million</td>
<td>$21.3 million</td>
<td>$6.0 million</td>
<td>28%</td>
</tr>
</tbody>
</table>
</figure>
 During the first quarter of 2025, the Company recorded its all-time quarterly sales record, exceeding the previous all-time high mark set during the fourth quarter of 2024 by 4%. The strong sales during the first quarter of 2025 helped, in part, reduce the backlog of orders to $4.0 million as of March 31, 2025, from $4.4 million as of December 31, 2024. Sales recorded during both the six-month and twelve-month periods ended March 31, 2025 also set all-time records for those periods.

Guidance

ICCC

ImmuCell Preliminary Q1 2025 Revenue Of $8.1M Up From $7.3M YoY; Reduced The Backlog Of Orders To $4M As Of March 31, 2025, From $4.4M As Of December 31, 2024

Maxim Group analyst Anthony Vendetti maintains Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) with a Buy and raises the price target from $75 to $100.

NUTX

Maxim Group Maintains Buy on Nutex Health, Raises Price Target to $100

Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The company reported quarterly sales of $33.585 million which beat the analyst consensus estimate of $31.019 million by 8.27 percent. This is a 25.79 percent increase over sales of $26.700 million the same period last year.

Earnings Beats

MAMA

Mama's Creations Q4 2025 GAAP EPS $0.04 Beats $0.03 Estimate, Sales $33.585M Beat $31.019M Estimate

SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=pRSoJS4egi5AoUvSmziXfzPTtM5867S_AYz5wh1jl-8Ed1C7_ZCqcFQS1o-NHlC0BB-egWkIvME-MZkyB4-OdDCBDAlrEzs49Q1A03dXhe0=">Vincerx Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger.
Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities.
"I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your contributions have meant everything. Although unprecedented, adverse market dynamics prevented us from continuing the development of our programs, numerous patients with cancer—who had few therapeutic options—benefited from our therapies in the Phase 1 trials. For the chance you gave us to help those patients, we thank you."

Biotech

VINC

Vincerx Pharma Announces That It Has Terminated Previously Announced Non-Binding Letter Of Intent With Global Digital Holdings Regarding a Potential Merger

KRUS

Kura Sushi Sees FY25 Total Sales $275M-$279M vs $280.741M Est.

Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS
Disease Education Campaign for Healthcare Providers called Move GBS Forward&#x2122; (<a href="https://www.globenewswire.com/Tracker?data=996SrP35r5vecT4gO1dn68T7-NUePhl8XXimJCcRwHmCgkXYb0D_5SQ1SsEFLJkdNq8q4igwk-1VFjEcxkDRtPgrMoYS0mAc08SQbfXVaWs=">MoveGBSForward.com</a>) Highlights Life-altering Impact of GBS
BRISBANE, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3aoQCjRMWzRCgOmEo2VMp7KZ5bz50dvEQZZc3CljQEL32ZpiRTVtfGcAVUmhmNrMweg52XAredlaKWzePcpVeA==">Annexon, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented data for its late-stage targeted therapy for GBS and showcased new disease education activities at the AAN Annual Meeting taking place April 5–9, 2025, in San Diego, California. An <a href="https://www.globenewswire.com/Tracker?data=aRK4M6Fm8iHnB2a1F_IqhDFZZgvGOI3PzKfCkaEzZVQIxvjAPAeUOzYjqm2ClGMZIthaGuevZBoKBoRM0OsnrbZoxJHLS9NSkpRt_D3yUkr3McPHK3viehUrMGAOV9qc0FMQfXxvTx3Cis7CKF1AudOFgNeXgX2SwZBhw_cAAXaqY2vVRsUMJUtxmZxBWno8">oral presentation today during the "Clinical Trials Plenary" session</a> featured results of the tanruprubart (formerly ANX005) Phase 3 placebo-controlled trial reinforcing its rapid and durable clinical benefits for patients with GBS. A replay of the session is available to AAN registrants.
GBS is a neuromuscular emergency that affects at least 150,000 people worldwide each year, with&nbsp;no FDA-approved therapies. The rare autoimmune disease is characterized by rapidly progressing and severe weakness that can lead to complete paralysis, often requiring intensive care and mechanical ventilation.
Tanruprubart is a first-in-kind monoclonal antibody designed to block C1q, the initiating molecule of the classical complement cascade. With a single infusion, tanruprubart halts ongoing neuroinflammation and nerve damage in the acute phase of GBS to improve and expedite overall recovery.

ANNX

Annexon To Present Pivotal Data On First Potential Targeted Therapy For Guillain-Barré Syndrome And Showcases New GBS Education Campaign At AAN 2025 Annual Meeting

NeOnc Technologies Holdings Announces Phase I Clinical Trial of NEO212 For Brain Cancer Nearing Full Enrollment.

Lake Street analyst Frank Takkinen maintains CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) with a Buy and lowers the price target from $19 to $14.

CVRX

Lake Street Maintains Buy on CVRx, Lowers Price Target to $14

As President Donald Trump initiated a tariff plan that many <a href="https://www.benzinga.com/25/04/44665530/jamie-dimon-once-a-tariff-supporter-warns-trumps-new-policy-could-slow-us-growth-fuel-inflation-the-quicker-the-issue-is-resolved-the-better">critics label stagflationary</a>, key figures in the Federal Reserve, including Mary Daly, president of the Federal Reserve Bank of San Francisco, signaled that the central bank might <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">delay further rate cuts</a>.
Daly, speaking at a moderated discussion at Brigham Young University on Tuesday, said she is comfortable with current interest rate levels, <a href="https://www.bloomberg.com/news/articles/2025-04-08/fed-s-daly-says-policy-is-in-good-place-amid-trade-uncertainty">reported </a>Bloomberg.
"We cut the interest rate by 100 basis points last year. That puts policy in a good place to stay modestly restrictive — keep inflation coming down — but not so restrictive that the economy is vulnerable," Daly told attendees.
Daly participates in the rate-setting Federal Open Market Committee as a rotating voting member. The Missouri native served on the committee in 2024 and is not currently a sitting member.
Daly said she thinks the committee should be careful when deviating from its current path.
"So, with growth good and policy in a good place, we've built the time and the ability to just tread slowly and tread carefully," she said.
Meanwhile, Fed Chair Jerome Powell has rebuked Trump&#8217;s overtures to policymakers to cut rates. Speaking at the Society for Advancing Business Editing and Writing conference on April 4, Powell said it&#8217;s &#8220;too soon&#8221; to assess a change in policy given the tariffs&#8217; impact on inflation.
According to the Federal Reserve Bank of St. Louis, the federal funds rate is currently 4.33%, lower than the 2024 peak of 5.33% but substantially higher than the low interest rate environment observed in the 2010s.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44698697/markets-reverse-gains-as-trumps-104-china-tariff-announcement-rattles-wall-street">Markets Reverse Gains As Trump&#8217;s 104% China Tariff Announcement Rattles Wall Street</a></li>
</ul>
Photo: Shutterstock

Government

Economics

Federal Reserve

San Francisco Fed's Mary Daly Says Central Bank Should 'Tread Slowly And Tread Carefully'

Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 7.69 percent. The company reported quarterly sales of $64.89 million which missed the analyst consensus estimate of $64.91 million by 0.03 percent. This is a 13.27 percent increase over sales of $57.29 million the same period last year.

Earnings Misses

Kura Sushi USA Q2 2025 Adj EPS $(0.14) Misses $(0.13) Estimate, Sales $64.89M Miss $64.91M Estimate

Crescent Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) ("Crescent" or the "Company"), today announced the simplification of its corporate structure by eliminating the Company's umbrella partnership-C corporation ("Up-C") structure through conversion of all remaining Class B common stock into Class A common stock, effective as of April 4, 2025 (the "Corporate Simplification").
As a result of the Corporate Simplification, all of the Company's stockholders now hold Class A common stock, with the same aligned economic and voting interests. The Company anticipates that simplifying its organizational structure and capitalization table will unlock shareholder value through reduced complexity, improving clarity of financial presentation, eliminating certain compliance and reporting costs, and enhancing accessibility for a broader pool of future investors.
There is no transfer of ownership contemplated in connection with the Corporate Simplification. KKR retains its existing 10% ownership, which is held by an indirect subsidiary of KKR &amp; Co. Inc. for its own account and not through its investment funds. KKR remains a committed long-term investor in Crescent, and as part of this Corporate Simplification, has agreed to a 180-day lock-up of its shares.
Crescent CEO David Rockecharlie said, "Today's announcement is in-line with our strategic goal of simplifying to grow, and we believe our streamlined corporate structure will deliver value to our existing Crescent shareholders while enabling us to expand our investor base and capital markets access.
Moreover, the Corporate Simplification is a result of the proactive approach our team has taken during this period of market volatility. With our consistent strategy, strong balance sheet and significant, well-hedged free cash flow generation, we believe we are well positioned to capitalize on opportunities for long-term value in any environment."

CRGY

Crescent Energy Transitions To Single Class Of Common Stock And Eliminates Up-C Structure

Loop Capital analyst Alton Stump maintains Dave &amp; Buster's Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) with a Buy and lowers the price target from $45 to $35.

PLAY

Loop Capital Maintains Buy on Dave & Buster's Enter, Lowers Price Target to $35

PANW

Palo Alto Networks shares are trading higher after the company announced it achieved $1.5 billion in sales on the Google Cloud Marketplace as of April 2025.

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are trading lower Tuesday as markets turned negative following confirmation from the White House that President Donald Trump's 104% retaliatory tariff on Chinese imports will <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44698697/markets-reverse-gains-as-trumps-104-china-tariff-announcement-rattles-wall-street">take effect Wednesday. </a> 
What To Know: The announcement came from White House Press Secretary Karoline Leavitt, who stated the administration would move forward with the full tariff package without delay or exemption. She emphasized the tariffs are a direct response to Chinese retaliation and are aimed at generating trillions in revenue while encouraging domestic production and reducing trade deficits.
The market, which had opened strong, reversed sharply following the announcement. The S&amp;P 500, which was in the green earlier, slipped 0.3%, while the Russell 2000 dropped 1.3%. The Nasdaq 100 held on to a narrow 0.1% gain, with momentum continuing to fade in afternoon trading.
Apple shares declined as concerns grew over how the company's supply chain and sales in China could be affected by the worsening trade environment. The tech sector, which initially led gains earlier in the session, also saw losses across major names. Tesla, Amazon and Apple all traded lower, with only Nvidia holding onto gains.
Federal Reserve officials also weighed in on the situation. Chicago Fed President Austan Goolsbee warned the economic drag from tariffs could be forming faster than data can capture. He called for quicker assessments of investment and GDP activity to track real-time impacts of protectionist measures.
With no indication of de-escalation and a midnight deadline for the tariffs to take effect, investors pulled back from risk and shifted focus to defensive sectors. Materials and consumer discretionary stocks led sector losses, reflecting concern over global trade disruption.
AAPL Price Action: Apple shares were down 6.59% at $169.50 at time of publication Tuesday, according to Benzinga Pro.
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08154439/Screenshot-2025-04-08-at-15.44.11-1024x530.png" alt="" class="wp-image-862666" style="width:436px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08154439/Screenshot-2025-04-08-at-15.44.11-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08154439/Screenshot-2025-04-08-at-15.44.11-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08154439/Screenshot-2025-04-08-at-15.44.11-768x397.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08154439/Screenshot-2025-04-08-at-15.44.11.png 1519w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44645681/jpmorgan-raises-recession-risk-to-60-as-largest-us-tax-hike-in-60-years-hits-global-economy">JPMorgan Raises Recession Risk To 60% As &#8216;Largest US Tax Hike&#8217; In 60 Years Hits Global Economy</a></li>
</ul>
Image Via Shutterstock.

Politics

Movers

Tech

AAPL

Apple Shares Drop As Trump's 104% China Tariff Escalation Sparks Market Reversal: What's Going On?

Loop Capital analyst Anthony Chukumba maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy and lowers the price target from $77 to $60.

Loop Capital Maintains Buy on Academy Sports, Lowers Price Target to $60

Press Releases

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Health Care

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

Clearside Biomedical's Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD  and Suprachoroidal Delivery Platform Highlighted at the  2025 Wet AMD & Diabetic Eye Disease Summit

Comments

Clearside Biomedical

Clearside Biomedical (CLSD) Opzioni

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO